Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $43.17 Consensus Target Price from Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has earned an average rating of "Buy" from the eight analysts that are covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $43.17.

ORKA has been the subject of several recent research reports. Wedbush restated an "outperform" rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. TD Cowen started coverage on Oruka Therapeutics in a research note on Monday, September 16th. They set a "buy" rating for the company. Jefferies Financial Group began coverage on Oruka Therapeutics in a research note on Friday, September 13th. They issued a "buy" rating and a $40.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, December 20th. Finally, Leerink Partners assumed coverage on Oruka Therapeutics in a research note on Tuesday, September 17th. They set an "outperform" rating and a $44.00 target price for the company.

Oruka Therapeutics Trading Down 4.9 %

Shares of NASDAQ:ORKA traded down $0.97 on Friday, hitting $19.01. The company had a trading volume of 133,976 shares, compared to its average volume of 93,721. The company has a market cap of $665.33 million, a PE ratio of -3.04 and a beta of 0.78. The stock's 50 day moving average is $23.95. Oruka Therapeutics has a 1-year low of $18.20 and a 1-year high of $53.88.

Institutional Investors Weigh In On Oruka Therapeutics

A number of institutional investors have recently made changes to their positions in ORKA. Geode Capital Management LLC bought a new stake in Oruka Therapeutics during the third quarter valued at $343,000. The Manufacturers Life Insurance Company acquired a new stake in Oruka Therapeutics during the third quarter worth approximately $1,037,000. Wellington Management Group LLP bought a new stake in Oruka Therapeutics in the third quarter worth approximately $2,013,000. Janus Henderson Group PLC acquired a new position in Oruka Therapeutics in the third quarter valued at approximately $5,840,000. Finally, Redmile Group LLC bought a new position in shares of Oruka Therapeutics during the 3rd quarter worth approximately $10,091,000. Institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.